SWX:NOVN
SWX:NOVNPharmaceuticals

How Novartis' Alzheimer’s Antibody Deal And US Radioligand Expansion At Novartis (SWX:NOVN) Has Changed Its Investment Story

In recent days, Novartis and SciNeuro Pharmaceuticals announced a worldwide licensing and collaboration deal to develop an amyloid beta antibody program for Alzheimer’s disease, while Novartis also unveiled plans for a new radioligand therapy manufacturing facility in Winter Park, Florida, as part of its multi-billion-dollar US investment. Together, these moves highlight how Novartis is pairing early-stage neuroscience innovation with expanded US radioligand production to deepen its...
SWX:TECN
SWX:TECNLife Sciences

Tecan Group (SWX:TECN) Posts Flat H2 Local-Currency Sales Is Its Recovery Story Credible?

Tecan Group AG has released unaudited preliminary results for fiscal 2025, reporting second-half sales growth of 0.4% in local currencies but a 5.2% decline in Swiss francs to CHF 443.0 million, with full-year sales down 1.6% in local currencies and 5.5% in Swiss francs to CHF 882.5 million versus 2024. The return to modest second-half growth, despite a full-year sales contraction, highlights a possible turning point in demand momentum amid currency headwinds and lingering operational...
SWX:IDIA
SWX:IDIABiotechs

Assessing Idorsia (SWX:IDIA) Valuation After Lucerastat Phase 3 Fabry Disease Results

Why the lucerastat data matters for Idorsia shares Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint. For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio. See our latest...
SWX:SREN
SWX:SRENInsurance

Is Swiss Re (SWX:SREN) Quietly Reframing Its Life Health Strategy With Heck’s New Leadership?

Earlier in January 2026, Swiss Re AG promoted Christophe Heck to market head Life Health for France, BeNeLux and Switzerland, with Heck now leading the Life Health reinsurance team from Zurich after more than a decade in the industry. This appointment places an experienced leader over several of Swiss Re’s core European Life Health markets, potentially influencing how the group prioritizes growth, risk selection and client engagement across the segment. We’ll now explore how Christophe...
SWX:SIKA
SWX:SIKAChemicals

Is It Time To Reassess Sika (SWX:SIKA) After A 30% One Year Share Price Slide?

If you have been wondering whether Sika shares are now offering value or still look expensive, this breakdown will help you put the current price into context before you commit fresh capital. Sika shares last closed at CHF149.10, with returns of an 8.7% decline over 7 days, a 6.7% decline over 30 days, an 8.9% decline year to date, and a 30.8% decline over 1 year, adding to a 39.6% decline over 3 years and a 35.0% decline over 5 years. Recent coverage around Sika has focused on its position...
SWX:ABBN
SWX:ABBNElectrical

How Investors Are Reacting To ABB (SWX:ABBN) Expanding Australian Smart Building Reach With Qantec Alliance

Qantec Automation has announced a new alliance with ABB to deliver open, sustainable smart building and IoT automation solutions across Australia, combining ABB’s building technologies with Qantec’s local market expertise. This collaboration highlights how ABB is using local distribution partnerships to deepen its presence in the smart building segment and support more efficient, lower‑emission infrastructure. We’ll now explore how ABB’s expanded Australian smart building footprint with...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Still Attractive After The Credit Suisse Integration And Strong Share Gains

If you are trying to work out whether UBS Group at about CHF 37.95 is still offering value or starting to look stretched, you are in the right place. The stock has returned 1.0% over the last 7 days, 10.5% over the last 30 days, 33.4% over the last year and very large gains over 3 and 5 years, while the year to date return sits at a 0.6% decline. Recent attention on UBS Group has been shaped by its integration of Credit Suisse and its evolving role as a major global wealth manager. These...
SWX:SQN
SWX:SQNCapital Markets

European Growth Companies Insiders Are Eager To Own

As European markets show optimism with the STOXX Europe 600 Index rising 2.27% amid a strengthening eurozone economy, investors are increasingly focused on growth companies that insiders are eager to own. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate confidence from those closest to the company's operations and potential for future success.
SWX:ABBN
SWX:ABBNElectrical

Assessing ABB (SWX:ABBN) Valuation After Strong Multi Year Shareholder Returns

Key business mix and where ABB makes its money ABB (SWX:ABBN) is a large industrial group built around four main businesses, each exposed to different parts of the global economy and electrification trends. Understanding this mix helps you see what really drives the stock. The Electrification segment supplies equipment such as power distribution products, circuit breakers, switchgear, and intelligent building and home systems. These offerings link ABB to utilities, building construction, and...
SWX:NWRN
SWX:NWRNPharmaceuticals

3 European Growth Stocks With Up To 31% Insider Ownership

As European markets continue to show optimism, with the pan-European STOXX Europe 600 Index rising by 2.27% amid positive economic signals and company earnings, investors are keenly observing growth companies that demonstrate strong insider ownership. In this environment, stocks with significant insider stakes can be appealing as they often indicate confidence from those closest to the company's operations and strategy.